Supernus Pharmaceuticals | SUPN - Cash And Equivalent

Stock Price
49.46
Daily Change
0.38 0.77%
Monthly
0.41%
Yearly
27.31%
Q1 Forecast
46.68

Supernus Pharmaceuticals reported $151.37M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
Abbott USD 7.51B 560M Sep/2025
ANI Pharmaceuticals USD 262.61M 44.81M Sep/2025
Aurora Cannabis CAD 95.69M 44.47M Sep/2025
Bristol-Myers Squibb USD 15.73B 3.13B Sep/2025
Canopy Growth CAD 298.06M 171.86M Sep/2025
Corcept Therapeutics USD 125.14M 22.39M Sep/2025
Eisai JPY 285.38B 19.82B Jun/2025
Eli Lilly USD 9.79B 6.42B Sep/2025
Novo Nordisk A/S DKK 18.44B 5.78B Jun/2025
Pacira USD 147.59M 152.89M Sep/2025
Perrigo USD 432.1M 22.1M Sep/2025
Pfizer USD 1.34B 295M Sep/2025
Supernus Pharmaceuticals USD 151.37M 6.66M Sep/2025
United Therapeutics USD 1.34B 253M Sep/2025
Xeris Pharmaceuticals USD 91.6M 32.32M Sep/2025